Alpelisib, a selective inhibitor of the p110α subunit of PI3K (3), has demonstrated substantial clinical efficacy in hormone receptor (HR)-positive, HER2/erbB2-negative breast cancers harboring PIK3CA mutations (4–6). This evidence concerns the gene NR4A1 and breast carcinoma.